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ABSTRACT
Mutations in DNA repair genes lead to increased genomic instability and mutation 
frequency. These mutations represent potential biomarkers for cancer immunotherapy 
efficacy, as high tumor mutational burden has been associated with increased neo-
antigens and tumor infiltrating lymphocytes. While mismatch repair mutations have 
successfully predicted response to anti-PD-1 therapy in colorectal and other cancers, 
they have not yet been tested for lung cancer, and few have investigated genes 
from other DNA repair pathways. We utilized TCGA samples to comprehensively 
immunophenotype lung tumors and analyze the links between DNA repair mutations, 
neo-antigen and total mutational burden, and tumor immune infiltration. Overall, 73% 
of lung tumors contained infiltration by at least one T cell subset, with high mutational 
burden tumors containing significantly increased infiltration by activated CD4 and 
CD8 T cells. Further, mutations in mismatch repair genes, homologous recombination 
genes, or POLE accurately predicted increased tumor mutational burden, neo-antigen 
load, and T cell infiltration. Finally, neo-antigen load correlated with expression of 
M1-polarized macrophage genes, PD-1, PD-L1, IFNγ, GZMB, and FASLG, among other 
immune-related genes. Overall, after defining the immune infiltrate in lung tumors, 
we demonstrate the potential value of utilizing gene mutations from multiple DNA 
repair pathways as biomarkers for lung cancer immunotherapy.
INTRODUCTION
Recent studies have uncovered that tumor types 
with high somatic mutation frequencies, such as non-small 
cell lung cancer (NSCLCs), melanoma, and colorectal 
cancer (CRC) [1], display the strongest responses to 
immune checkpoint inhibitors [2–7]. This link between 
mutational burden and immunotherapy efficacy is due to 
the generation of immunogenic, tumor-specific mutated 
peptides, termed neo-antigens. Neo-antigens have been 
linked to response to anti-PD-1 therapy in NSCLC [8] 
and anti-CTLA-4 therapy in melanoma [9]. Further, in 
muscle invasive bladder cancer, high neo-antigen load 
correlated with greater recurrence-free survival and low 
T cell receptor-β diversity, indicating oligoclonal T cell 
expansion [10]. Across multiple cancer types, predicted 
neo-antigen burden, but not overall mutational load, 
correlated with patient survival and CD8A and PD-1 
expression [11], as well as immune cytolytic activity 
(GZMA and PRF1 expression) [12]. 
The clinical significance of neo-antigens is derived 
from their ability to drive a functional and specific anti-
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tumor immune response. Neo-antigen-specific T cells 
have been identified in chronic lymphocytic leukemia 
patients who demonstrated remission after allogeneic 
stem cell therapy [13], melanoma patients who were 
administered an IL-12-producing dendritic cell vaccine 
(after prior ipilimumab therapy) [14], as well as phase 
II melanoma patients who experienced tumor regression 
after adoptive transfer of autologous tumor infiltrating 
lymphocytes (TILs) [15]. In pre-clinical studies, multiple 
immunogenic mutated peptides capable of decreasing 
tumor growth in vivo were identified in the B16F10 
melanoma cells line [16], and in a murine sarcoma 
model, tumor immunoediting led to clonal outgrowth 
of tumor cells lacking neo-antigen expression [17]. 
Further, immunization with neo-antigens has even proven 
therapeutically comparable to administration of immune 
checkpoint blockade in mice [18]. This therapeutic 
potential was translated to the clinical setting, as adoptive 
transfer of autologous tumor mutation-specific Th1 CD4 
T cells from a patient with metastatic cholangiocarcinoma 
was able to induce tumor regression upon original 
administration as well as after tumor recurrence [19]. 
One potential driver of a hypermutable state 
capable of generating neo-antigens is the loss of DNA 
repair genes [20]. In CRC, mismatch repair (MMR) gene 
mutations differentiate microsatellite instable (MSI) 
from microsatellite stable (MSS) disease. Interestingly, 
MSI CRCs contain increased mutations, predicted neo-
antigens, TILs (with a Th1 phenotype), and expression 
of immunosuppressive molecules, and MSI also confers 
a favorable prognosis [21–27]. Mutated MMR genes 
themselves have even been postulated as immunogenic 
antigens capable of driving the immune response in 
pancreatic cancer [28]. Importantly, in a phase 2 trial 
of metastatic CRC patients treated with the anti-PD-1 
antibody, pembrolizumab, patients with MMR-deficient 
tumors had a objective response rate (ORR) of 40%, 
compared to 0% for those with MMR-proficient tumors. 
Similarly, patients with MMR-deficient non-CRC had a 
ORR of 71%. These MMR-deficient tumors contained 
significantly increased mutation and neo-antigen load, 
both of which were associated with increased progression-
free survival [6]. Importantly, similar success has been 
replicated in MSI-high CRC [29] and across multiple 
other cancer types [30], leading to pembrolizumab being 
granted FDA approval for use in unresectable or metastatic 
MMR-deficient or MSI-high solid tumors. However, none 
of the above studies have demonstrated efficacy in MMR-
deficient lung tumors, and immunotherapy clinical trials 
have only focused on the MMR DNA repair pathway. 
In addition to mutations in MMR genes, deficiencies 
in other DNA repair genes have also been implicated 
in neo-antigen generation and impacting the immune 
response. BRCA1/2 and other homologous recombination 
(HR) gene mutations have been associated with increased 
neo-antigen load, CD3 and CD8 TILs, expression of 
cytotoxicity-related genes (in the TCR, IFNγ, and TNFR 
pathways), PD-1 and PD-L1 expression, and favorable 
overall survival (OS) in ovarian cancer [31, 32]. In 
endometrial cancer, samples with POLE mutations have 
shown increased neo-antigens, as well as PD-1 and PD-
L1 expression [33]. Further, in NSCLC patients treated 
with anti-PD-1 blockade, responders with the highest 
mutational burden contained mutations in POLD1, 
POLE, and MSH2, and nonsynonymous mutational 
burden and neo-antigen load in these patients correlated 
with enhanced clinical response [8]. This effect of DNA 
repair loss to augment the anti-tumor immune response 
can explain the improved clinical outcomes and survival 
seen in patients with tumors harboring mutations in these 
critical genes [34–36]. 
In lung adenocarcinoma, nivolumab immunotherapy 
is approved for patients progressing on platinum-
based chemotherapy, conferring a 51% 1 year OS rate 
compared to 39% with docetaxel [37]. Additionally, 
pembrolizumab is approved for PD-L1-positive metastatic 
NSCLC patients, with a reported 19.4% ORR and 12 
month median OS (treated population was 81% non-
squamous NSCLC) [5]. However, while neo-antigen 
and mutational burden have been linked to enhanced 
response to immunotherapies [8], biomarkers to aid in 
identifying these patients are lacking. In addition, the 
overall immunophenotype of the lung adenocarcinoma 
microenvironment still has not clearly been defined in a 
comprehensive manner. We hypothesize that mutations in 
DNA repair genes in lung adenocarcinoma are key players 
in determining total mutational burden, neo-antigen load, 
and, consequently, tumor microenvironment in increased 
TILs and immune infiltrate that can serve as future 
biomarkers for immune checkpoint efficacy. 
RESULTS
The immunophenotype of lung adenocarcinoma 
is primarily infiltration by activated CD4 and 
CD8 T cells
To elucidate the immune microenvironment of 
TCGA lung adenocarcinoma samples, we utilized a pre-
determined list of immune metagenes whose expression 
have been shown to accurately predict the infiltration 
of 28 immune cell populations [24]. Activated CD4 and 
activated CD8 T cells were the most prominent infiltrating 
cell types, present in 29.7% and 26.8% of samples, 
respectively. Infiltration by at least one T cell subtype was 
identified in 73% of samples (Figure 1A). Additionally, 
we analyzed the tendency for each pairing of immune 
cell types to infiltrate the same samples. Interestingly, 
infiltration by activated CD4 and CD8 T cells significantly 
co-occurred in the same tumors, and infiltration by both 
cell types also significantly co-occurred with myeloid 
dendritic cells (mDCs), effector memory CD4 T cells, 
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and Th17 T cells, with both inversely correlating with 
activated B cells, immature B cells, regulatory T cells 
(Tregs) and γδ T cells (Figure 1B). 
Tumors with higher mutational burden contain 
increased TILs and a distinct molecular and 
histological phenotype
Mutational burden is known to impact tumor 
immunogenicity. To determine how the immunophenotype 
of lung adenocarcinoma is affected by increased 
mutational burden, we divided samples into those above 
or below the median mutation count. As expected, 
patients with tumors with high mutational burden were 
heavier smokers (Supplementary Figure 1A, 1B) and 
contained increased cytosine to adenine transversions 
(Supplementary Figure 1C), which has been previously 
linked to smoking [38–40]. Interestingly, the high mutation 
group also contained significantly higher infiltration by 
effector memory CD4 T cells, activated CD4 and CD8 T 
Figure 1: Comprehensive immunophenotype of the lung adenocarcinoma microenvironment. (A) Percent of tumors with 
positive infiltration by each adaptive (black bars) and innate (gray bars) immune cell type, as determined by immune metagene lists and 
GSEA analysis. Abbreviations: γδ T (TGD) cells, immature DCs (iDCs), myeloid derived suppressor cells (MDSCs), follicular helper 
T (TFH) cells. (B) Heat map indicating infiltration of immune cell types that either significantly (*P < 0.05) co-occur or are mutually 
exclusive within tumors. 
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cells, mDCs, any T cell type, and any immune cell type 
(Figure 2A). Additionally, tumors with higher mutational 
burden were less likely to be oncogene-positive, as defined 
by containing an activating mutation in the RTK/RAS/
RAF signaling pathway (Figure 2B). These tumors were 
also associated with a cluster 2 or 3 classification, defined 
by increased TP53 mutations, tumor ploidy, and copy 
number variations (CNVs) in 8q, 15q, and chromosome 
7. High mutation tumors were less commonly cluster 
4 samples, which are defined by low ploidy, 6q CNVs, 
CDKN2A methylation, and SETD2 mutations (Figure 
2C). Finally, high mutation tumors were more often 
histologically proximal-inflammatory (squamoid; NF1 
and TP53 mutations) or proximal proliferative (magnoid; 
KRAS mutation, STK11 inactivation), and significantly less 
likely to be terminal respiratory unit (bronchioid; EFGR 
mutations and kinase fusions) [38] (Figure 2D). 
DNA repair-deficient tumors contain increased 
mutation count, TILs
Mutations in DNA repair genes can consequently 
result in a hypermutable state with increased genomic 
instability. To test our hypothesis that mutations in 
these single DNA repair genes can serve as biomarkers 
for identifying NSCLC patients with higher mutational 
burden and increased TILs, we analyzed tumors 
specifically containing mutations in the HR pathway, the 
MMR pathway, or POLE. In each grouping, tumors with 
DNA repair deficiencies displayed significantly increased 
mutation counts (and a trending further increased mutation 
count with multiple HR and MMR genes mutated) (Figure 
3A.i, 3B.i, 3C.i). Samples with HR mutations were 
significantly more infiltrated by activated CD4 T cells, 
neutrophils, natural killer T (NKT) cells, and were less 
likely to be infiltrated by activated B cells. Those with 
MMR mutations contained increased T cell infiltration, 
and POLE mutated samples contained increased 
infiltration by effector memory CD4 T cells, Th17 T cells, 
natural killer (NK)56 bright cells, T cells, plasmacytoid 
DCs (pDCs), Th1 T cells, and cytotoxic cells (Figure 
3A.ii, 3B.ii, 3C.ii). 
We next analyzed the link between DNA repair gene 
mutations and mutations in type I interferon (IFN) genes, 
as tumor-derived type I IFNs are important for optimal 
immunosurveillance and anti-cancer therapy efficacy 
[41]. Samples with HR, MMR, and POLE mutations all 
contained increased frequencies of mutations in various 
type I IFN pathway genes. Notable, HR mutated tumors 
contained increased IFNβ (IFNB1) and IRF8 (type I IFN 
positive feedback loop) mutations, while MMR mutated 
tumors contained increased IFNα (IFNA5, IFNA14, 
Figure 2: High mutation burden tumors contain increased TILS, immune infiltration, and a distinct molecular 
phenotype. (A) Fold change in the percent of patients with adaptive (black bars) and innate (gray bars) immune cell infiltration in those 
with high compared to low mutation burden, as defined by the median mutation count (excluding cell types with positive tumor infiltration 
in < 10 samples). Percent of high and low mutational burden tumors classified by (B) oncogene-positivity, (C) cluster type, and (D) 
histology. * P < 0.05, ** P < 0.01, *** P < 0.001.
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IFNA21) and IFNAR2 (type I IFN receptor) mutations 
(Supplementary Figure 2A–2C), thereby indicating 
that while mutations in DNA repair genes are linked to 
increased tumor mutation count and TILs, they also 
may represent tumors with increased type I IFN gene 
mutations. Similarly, we also analyzed potential immune 
evasion as a result of mutations in class I HLA genes [42]. 
However, class I HLA mutations in the TCGA dataset we 
rare, with only 3, 0 , and 1 of the 230 samples containing 
mutations in HLA-A, HLA-B, and HLA-C, respectively. 
Of those, the 3 HLA-A mutated samples did not contain 
HR, MMR, or POLE mutations, while the single HLA-C 
mutated sample did contain a mutated HR pathway (data 
not shown). 
Neo-antigen burden is linked to DNA repair 
mutations, increased TILs
The clinical and immunological relevance of 
increased mutational burden is that as more tumor 
mutations arise, there is a greater likelihood for somatic, 
non-synonymous mutations to result in the formation of 
immunogenic epitopes expressed only in cancerous cells. 
Therefore, we filtered total non-synonymous mutations 
into predicted neo-antigens, as determined by predicted 
immunogenicity (MHC binding affinity) (Supplementary 
Figure 3A), positive gene expression (Supplementary 
Figure 3B), and those whose non-mutated parental epitope 
were weak or non-MHC binders (Supplementary Figure 
3C). Similar to total mutation count, neo-antigen burden 
was also significantly higher in samples with HR, MMR, 
or POLE mutations (Figure 4A–4C). Additionally, those 
samples with high neo-antigen load contained significantly 
increased infiltration by any immune cell type, overall T 
cells, activated CD8 T cells, and effector memory CD8 T 
cells (Figure 4D). 
Neo-antigens correlate with increased expression 
of multiple pro-inflammatory cytokines 
and immune-related genes, M1-polarized 
macrophage genes, PD-L1 and PD-1, and 
favorable survival outcome
While the link between neo-antigen load and TILs 
is now appreciated in many cancer types, the specific 
molecular causes and consequences of that association 
Figure 3: DNA repair mutations are biomarkers for total mutational burden and TILs. Total mutation count of tumors 
with mutations in (A.i) HR genes, (B.i) MMR genes, or (C.i) POLE. Results are presented as mean ± SEM. (A.ii), (B.ii), (C.ii) Percent of 
DNA repair wildtype (WT; black bars) or mutated (Mut; gray bars) tumors with immune cell infiltration (all immune cell types with P < 
0.1 displayed. Red dotted line separates increased and decreased tumor infiltrating immune cell types). * P < 0.05, ** P < 0.01, *** P < 0.001.
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are not as well understood. We analyzed the correlations 
between neo-antigen burden and the expression of 
a comprehensive list of cytokines, chemokines, and 
immunomodulatory genes [24]. Significant positively or 
negatively correlated genes are reported in Figure 5A. 
Increasing neo-antigen load correlated with chemokines 
TNFRSF25, CCR1, and LTBR, immunomodulatory genes 
LAG3, PDCD1 (PD-1), GZMB, and FASLG, and multiple 
cytokines/cytokine receptors, including IFNγ, IL12RB2, 
and IL17RA. Additionally, when analyzing expression of 
gene markers to differentiate pro-inflammatory M1 from 
immunosuppressive M2 tumor-associated macrophages 
(TAMs) [43], tumors with more neo-antigens displayed 
significantly increased expression of M1 genes NOS2 
and IL23A, and significantly (SOC2) or trending (CHIA, 
CHI3L1, CHI3L2, KLF4) decreased expression of multiple 
M2-associated genes (Figure 5B). Further, the top quartile 
of high neo-antigen load samples displayed increased 
PD-L1 (Figure 5C) and PD-1 (Figure 5D) expression. 
Finally, these high neo-antigen load patients trended 
toward increased OS (p = 0.12 when excluding the low 
neo-antigen outlier censored at 224 months) (Figure 5E). 
DISCUSSION
Recent scientific and clinical advances in cancer 
immunotherapy have highlighted the importance of 
understanding neo-antigens and the immunological tumor 
microenvironment. Specifically in lung cancer, immune 
checkpoint blockade has shown great promise. However, 
we are still lacking a comprehensive understanding of the 
immunophenotype of these tumors. Additionally, while 
deficiencies in DNA repair genes, mostly in the MMR 
pathway, are known to accelerate mutation rates and 
affect prognosis, their relevance in immunotherapy in lung 
cancer has been unclear. 
We first analyzed immune cell infiltration, utilizing 
a comprehensive list of “immune metagenes” to accurately 
predict the presence of up to 28 intra-tumoral immune cell 
types in a large cohort of lung adenocarcinoma patients. 
Interestingly, activated CD4 and CD8 T cells were the 
most commonly infiltrating cell types, followed by mDCs, 
all of which are desired for an optimal anti-tumor response. 
73% of the samples were infiltrated by at least one of the 
T cell subtypes (Figure 1A). Further, activated CD4 and 
CD8 T cells were low in tumors infiltrated by activated B 
cells or immature B cells (Figure 1B), in agreement with 
a study demonstrating increased CD8 tumor infiltration 
and decreased tumor growth after B cell depletion [44]. 
Activated CD8 and CD4 infiltrated tumors also contained 
decreased infiltration by Tregs but increased Th17 T cell 
infiltration. Differentiation of T cells into either of these 
cell types inhibits the generation of the other, yet while 
Tregs are known to promote immunosuppression and 
tumor growth [45], intra-tumoral Th17 T cells can increase 
IFNγ production and tumor infiltration by CD8 TILs, NK 
cells, and DCs [46]. Also of note, tumors infiltrated by 
activated CD4 and CD8 T cells also contained increased 
infiltration by γδ T cells, which can also promote the anti-
tumor immune response [47]. 
Figure 4: DNA repair mutations are biomarkers for high tumor neo-antigen load, which is associated with increased 
TILs. Neo-antigen count of tumors with (A) HR, (B) MMR, or (C) POLE mutations. Results are presented as mean ± SEM. (D) Percent 
of neo-antigen low (black bars) or high (gray bars) patients infiltrated by immune cell types (all immune cell types with P < 0.1 displayed). 
* P < 0.05, ** P < 0.01, *** P < 0.001.
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We next sought to determine the significance of 
mutational burden on the immunological response in 
lung adenocarcinoma. As hypothesized, tumors with 
high mutational count displayed increased infiltration 
by activated CD4 and CD8 T cells, effector memory 
CD4 T cells, and mDCs (Figure 2A). Importantly, 
tumors containing mutations in HR genes, MMR genes, 
or POLE contained significantly higher mutational 
load than DNA repair wildtype tumors, and similarly 
contained significantly increased infiltration by many 
of the T cell types and other immune cells desirable for 
anti-tumor activity. Further, HR-deficient tumors also 
contained decreased infiltration by B cells, a potentially 
immunosuppressive and tumor-promoting cell type [48] 
(Figure 3). Therefore, detecting mutations in the single 
POLE gene or the small HR or MMR gene lists can 
accurately be used as biomarkers for identifying patients 
whose tumors likely contain high mutational burden and, 
consequently, increased TILs. 
To clarify the clinical relevance of these findings, we 
refined overall mutational burden to specifically consider 
at predicted immunogenic neo-antigens. HR-, MMR-, and 
POLE-deficient tumors again contained increased neo-
antigens and T cell infiltration (Figure 4). Interestingly, 
increasing neo-antigen load strongly positively correlated 
with expression of many immune-related genes. Notably, 
neo-antigens increased with increasing expression of IFNγ 
and IL12RB2, indicating a Th1 skewed signature, as is 
desirable in an anti-tumor response. Neo-antigen load also 
correlated with increased expression of IL23A, IL21, and 
IL17RA, all of which are players in the Th17 T cell pathway, 
which is implicated in both tumorigenesis as well as the anti-
tumor immune response [46]. Also correlating were GZMB 
and FASLG, both necessary for anti-tumor CD8 T cell 
cytotoxic functionality [49], PD-1 and LAG3, representing 
T cell activation and exhaustion [50], and TAP2, necessary 
in MHC I antigen presentation [51]. Cytokines inversely 
correlating with neo-antigen burden included TSLP and 
Figure 5: Neo-antigen load correlates with multiple immune-related genes and cytokines, M1-polarized TAMs, PD-L1, 
PD-1, and favorable OS. (A) Pearson correlation coefficients between neo-antigen count and RNA-seq expression levels of multiple 
chemokines, immunomodulatory genes, and cytokines (only significantly correlating genes reported). (B) Expression of M1 TAM- and M2 
TAM-defining genes in high and low neo-antigen burden tumors (all genes with P < 0.2 displayed). (C) PD-L1 and (D) PD-1 expression in 
high (top quartile) and low neo-antigen load tumors. Results are presented as mean ± SEM. (E) OS of neo-antigen load high (top quartile) 
and low tumors. * P < 0.05, ** P < 0.01, *** P < 0.001.
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IL33, involved in the Th2 response [52], IL7, implicated 
with pro- and anti-tumorigenic properties [53], EDA2R, 
which is involved in p53 signaling [53], and multiple genes 
in the TRAIL apoptosis pathway. Additionally, neo-antigen 
load correlated with increased expression of the chemokines 
TNFRSF25, CCR1, and LTBR, which may serve as valuable 
targets in future tumor immunology studies (Figure 5A). 
Outside of T cells, TAMs have emerged an important 
focus of research and therapeutic targets. Specifically, 
M1-polarized macrophages have been shown to promote 
anti-tumor activity and decrease tumor growth while M2 
macrophages suppress TILs and promote tumorigenesis 
[54]. We found that high neo-antigen load correlated with 
increased expression of multiple M1 genes and decreased 
expression of multiple M2 genes. This finding supports a 
novel link between neo-antigens and M1 TAM polarization. 
This may be due to the interplay between an increased 
activated adaptive T cell response with a Th1/Th17 
signature and the infiltrating innate cells. Finally, tumors 
with increased neo-antigens contained increased expression 
of PD-L1 (Figure 5C), which is induced by IFNγ [55], 
and PD-1 (Figure 5D), as well as a trending increase in 
OS (Figure 5E). While past studies have reported a more 
dramatic gap in survival between high and low neo-antigen 
groups, our analysis was limited because for the TCGA data 
the treatments and disease stage were not controlled between 
groups, many patients were censored at early time points, 
and many patients had resectable early stage disease as 
opposed to late stage disease important for survival analysis. 
Overall, we comprehensively analyzed the 
immunophenotype of the lung adenocarcinoma 
microenvironment. This study demonstrates that lung 
tumors with DNA repair deficiencies, either in the 
MMR pathway, HR pathway, or POLE, can be utilized 
as biomarkers for total mutational burden, neo-antigen 
load, and TILs, which will be of utmost value as 
immunotherapies continue to grow and expand clinically. 
These results provide a foundation for further studies 
exploring the clinical implications of using DNA repair 
gene mutations as a predictive marker for immunotherapy 
response. 
MATERIALS AND METHODS
Clinical data, immune infiltration, DNA repair
This study utilized cBioPortal [56, 57] to obtain 
data from the lung adenocarcinoma cohort of The Cancer 
Genome Atlas (TCGA) [38] to analyze RNA-sequencing 
(RNA-seq) gene expression and clinical data (n = 515) 
and DNA mutations (n = 230). Predicted infiltration by 28 
distinct immune cell types was performed as previously 
described [24], utilizing 812 “immune metagenes” derived 
from 813 microarrays over 36 studies. Expression of these 
genes was used as input in Gene Set Enrichment Analysis 
(GSEA), and any immune cell types with a false discovery 
rate (q-value) of ≤ 10% were considered as positively 
infiltrating into that tumor sample. In the DNA repair genes 
analysis, the homologous recombination pathway gene list 
included ATR, ATM, CHEK1, CHEK2, BRCA1, BRCA2, 
BAP1, BARD1, FANCD2, FANCE, FANCC, FANCA, 
RAD50, RAD51, and PALB2, and the mismatch repair 
pathway gene list included MLH1, MLH3, MSH2, MSH3, 
MSH4, MSH5, MSH6, PMS1, PMS2, PMS2L3, PCNA, 
EXO1, POLD1, RFC1, RFC2, RFC3, RFC4, and RFC5 
[58]. In the type I IFN signaling pathway analysis, the gene 
list included all genes with available TCGA data from the 
gene ontology (GO) accession number 0060337 [59, 60]. 
Neo-antigen prediction
HLA typing, neo-antigen identification, and 
HLA-peptide affinity prediction were performed using 
HLAminer [61],Variant Effect Predictor Tool [62], 
NetMHCpan [63], and the UCSC browser [64] (http://
www.genome.ucsc.edu/), with most computations 
performed on the National Cancer Institute (NCI) Cancer 
Genomics Cloud (CGC) in the Seven Bridges Genomics 
implementation. The neo-antigen affinity scores were 
generated between all possible 9 amino acid length 
peptides containing a mutated site with the 6 predicted 
HLA types, using the CloudNeo pipeline [65]. A control 
analysis was performed with the homologous non-mutated 
9 amino acid length sequences. Neo-antigens were defined 
as mutated peptides with a binding score IC50 < 500 nM, 
positive gene expression, and whose non-mutated wildtype 
peptide was a weak or non-MHC binder IC50 > 500 nM. 
Statistical analysis
As appropriate, z-score between two population 
proportions, unpaired two-tailed Student’s or Welch’s t-test, 
Log-rank test for survival, and the Pearson correlation 
coefficient were used for statistical assessment. Results 
are presented as percentages, fold change (logarithmic 
scale), mean ± standard error of the mean (SEM), Pearson 
correlation coefficient, RNA-seq z-score, or percent survival, 
as indicated. * P < 0.05, ** P < 0.01, *** P < 0.001.
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